Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

H2020-FTI: Búsqueda de hospitales y socios industriales para realizar ensayos clínicos de un nuevo tratamiento para el cáncer de páncreas

Resumen

Tipo:
Búsqueda de socios
Referencia:
RDES20160415001
Publicado:
21/04/2016
Caducidad:
21/04/2017
Resumen:
Una pyme española del área de oncología está interesada en presentar una propuesta al esquema Fast Track to Innovation del programa Horizonte 2020 con el fin de realizar la prueba de concepto y validar un nuevo tratamiento para el cáncer de páncreas. El medicamento biológico, que ya se comercializa para otras indicaciones, podría ser un nuevo tratamiento para el cáncer de páncreas que sirva para mejorar considerablemente las terapias actuales. La empresa busca un hospital, un fabricante de fármacos y una organización de investigación por contrato (OIC) para completar el consorcio. La fecha límite de la convocatoria es el 1 de junio de 2016.

Details

Tittle:
H2020-FTI: Hospitals and industrial partners are being sought to perform clinical trials for a new pancreatic cancer treatment.
Summary:
A Spanish SME is willing to submit a project proposal within the Horizon 2020 Fast Track to Innovation scheme that aims to proof and validate a new treatment for pancreatic cancer. A hospital, an industrial drug manufacturer and a contract research organisation (CRO) are being sought to fulfil the consortium. Call deadline: 01/06/16
Description:
The company seeks partners to perform the proof of concept for clinical trials on patients affected by pancreatic cancer with the goal of validating the efficacy of a reprofiled drug.
The Spanish SME operating in the oncology area is developing a new treatment for pancreatic cancer. The biological drug already commercialized for other indications could be a new treatment for pancreatic cancer significantly improving current therapies. Efficacy preclinical studies in vivo have been performed by the SME and the safety profile of the drug is completely known and documented as the drug is on the market. A patent application has already been submitted. The SME is seeking hospitals, drug manufacturing companies and CRO´s to test the medicine on this new indication. The drug should be administered to minimum 20 adult patients for a period of time of 3 months.
Hospitals and CRO partners should be experts in cancer disease clinical trials, especially pancreatic cancer and skilled to draw up protocols and reports. The drug manufacturing company should be expert in biological or biosimilar drugs, under good manufacturing practices (GMP) protocols. The hospital will be allowed to publish the results after being reviewed by the SME.

H2020 call: Fast Track to Innovation.
Call deadline: 01/06/16
Deadline for EoIs: 20/05/16

Partner sought

Partner Sought:
Type of partners sought: - Hospital - Industrial drug manufacturer - CRO (contract research organisation) Field of expertise: Hospital and CRO: Pancreatic cancer, European project coordination. Drug Manufacturer: Biological drug Task to be performed: Hospital: clinical trial; CRO: writing protocols and reports, data managing, statistics. Industrial partner: drug manufacturing, labelling and distribution.
Type of Partnership Considered:
RDR

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Spanish

Dissemination

Programme-call

Evaluation Scheme:
FTI
Anticipated Project Budget:
3.000.000-Y-euro;
Coordinator Required:
Si
Deadline for Call:
01/06/2016
Project Duration:
105